logo
Forget Timelines. How To Let Go Of Outdated Societal Expectations

Forget Timelines. How To Let Go Of Outdated Societal Expectations

Forbes28-03-2025

Societal timelines often dictate when we should reach life milestones—but breaking free from them ... More can lead to greater fulfillment, mental well-being and self-defined success.
From the moment we understand the world around us, societal norms and timelines shape our expectations of ourselves and others: graduate by 22, build a career by 30, marry by 35, peak professionally by 45 and retire by 65. This 'social clock' heavily influences people's decisions, often pushing them to act in ways that align with the expectations of their culture rather than their own goals or readiness. According to The Mind & Company, this influence operates consciously and unconsciously, creating internalized pressure to meet milestones at specific ages. Over time, these pressures can significantly impact mental health—contributing to feelings of persistent inadequacy, anxiety, and self-doubt.
The impact of these societal norms extends well beyond life choices—it deeply affects mental health. Individuals who don't align with these norms report higher levels of stress, lower self-esteem and symptoms of depression. These emotional challenges are exacerbated by constant comparison and fear of judgment.
Research published by the National Center for Biotechnology Information highlights a growing rise in mental health issues, including anxiety and depressive disorders, tied to increasing social pressures and perceived inequality. The more society clings to rigid timelines, the more it contributes to widespread psychological distress, making it critical to question and redefine what it truly means to be 'on time' in life.
While many continue to chase societal milestones—often at the expense of their well-being—others are choosing a different path, one guided by personal fulfillment over public expectation. Few embody this shift more clearly than Elizabeth Talerman. A brand consultant and founder and partner of the Nucleus Group, Talerman was 60 when she finally felt she was living her best life.
After decades of strategic work, building her firm and saying 'yes' to what was expected of her, she pivoted—intentionally. Not because society said it was time to retire, get married or slow down, but because she chose to live on her own terms.
'I live in a universe of my own—the Elizabeth-verse,' she said, 'with the mantra of 'I go on, I exist and I am enough.'' It's a mindset that took years to adopt but one that shielded her from the paralyzing pressure many feel when they don't meet traditional milestones 'on time.'
Elizabeth Talerman, partner at the Nucleus Group, at The Center for Fiction.
As Talerman points out, none of the conventional trappings, whether the wedding industrial complex or the corner office, matter if they don't nourish you.
Instead of focusing on 'supposed to,' she asked, 'Where does my energy make the most difference?' It's a question rooted in self-awareness and impact, not obligation. That clarity doesn't come from conforming; it comes from choosing.
Talerman has had a successful career spanning nearly 40 years in branding and marketing. She served as marketing director at Harvard Business School before being recruited by Ogilvy, where she worked on the IBM account. Soon after, she launched her consultancy, growing it into a respected strategic agency.
Despite her professional accomplishments, she never let societal timelines dictate her strategy or goals. She didn't marry young or retire at 65. Instead, she got married for the first time at 60, after more than a decade in a deeply fulfilling relationship. Rather than completely stepping away from work, she transitioned from full-time leadership into consulting on projects that align with her values. For her, this was realignment. She calls it 'freedom money,' the ability to invest her time and energy into what brings her joy and creates lasting impact. In doing so, Talerman created space for love, purpose, and presence on her terms and in her time.
The truth is that societal timelines are often more about commerce than care. They sell an idea of success, love and happiness that's easy to market but frequently false in reality. Breaking free from them is the real journey.
Talerman concluded, 'Life is a lean in, lean forward and learn forward endeavor.' And there's no deadline for that.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

2 Iowa teens attend Type 1 diabetes Children's Congress in Washington, D.C.
2 Iowa teens attend Type 1 diabetes Children's Congress in Washington, D.C.

Yahoo

timea day ago

  • Yahoo

2 Iowa teens attend Type 1 diabetes Children's Congress in Washington, D.C.

DES MOINES, Iowa — Two teenagers from Iowa joined youth from across the world at the Breakthrough T1D Children's Congress in Washington, D.C. this weekend. Every two years, the Children's Congress brings youth from across the world to Washington D.C. to share their Type 1 diabetes stories with Federal lawmakers. This year, the delegates are visiting from June 7 -9 and represent Breakthrough T1D groups across all 50 states, Australia, Canada, Israel, the Netherlands, and the United Kingdom. Greek Food Fair Festival helps keep Church in community The youth will act as delegates who share their stories and the stories of others, while engaging in leadership and advocating for continued research funding. This year, two delegates from Iowa, Elizabeth and Sachin, are sharing their stories. Elizabeth, 17, is from Adel and was diagnosed with T1D at 14 years old, just days before the Super Bowl. She says seeing Noah Grey on the field reminded her that she could do anything. Elizabeth has built a T1D community through sharing tips and tricks, and hopes it helps others feel less alone. Elizabeth enjoys connecting with the community through her job and volunteering, she hopes to open her own business in the future. Sachin, 13, was diagnosed with T1D at 10 and loves everything engineering. Sachin enjoys making fun inventions that bring laughter, and practical ones like a new kind of insulin pump he designed for his recent science fair project. Since his diagnosis, Sachin has attended walks, galas, and summits to support Breakthrough T1D and learn about exciting new technology that could help those living with Type 1 diabetes. Visit the Breakthrough T1D website to learn more about the Children's Congress and the 170 delegates. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.

Safety expert warns of scammers selling free online courses
Safety expert warns of scammers selling free online courses

Yahoo

time2 days ago

  • Yahoo

Safety expert warns of scammers selling free online courses

A Chorley safety expert has warned the public about online scammers charging people for his content. Dale Allen, founder of the Safety-Verse, said "copycat" companies have been taking his freely available health and safety courses and selling them to unsuspecting users. The Safety-Verse offers certified training through The Knights of Safety Academy, covering topics such as online safety, Control of Substances Hazardous to Health (COSHH) regulations, and mental health awareness. Mr Allen said: "For years, we have proudly provided free health and safety training to over 300,000 students to help people upskill, stay safe and build careers. "Our mission has always been rooted in one thing—access for everyone with no barriers. "These resources were created to save lives, not to be exploited for profit behind closed doors. "The misuse of our content without permission is deeply disappointing, unethical and unlawful." Mr Allen said "copycat" sites were not only charging for the free courses, but also issuing the Knights of Safety Academy's official certificates as if they were their own. He is now advising people to access the courses through the official Safety-Verse platform and to report any websites offering the training for a fee. While the copying activity is a breach of copyright law, Mr Allen said his bigger concern was that people were being exploited. Mr Allen added: "It's not just about the law, it is the principle. "People deserve honesty and clarity and we want to protect the value of free, open safety education." He also warned the public to be cautious of similar schemes online, including websites that charge for government services which are otherwise free, such as getting a tax refund from HMRC or applying for child benefit. The 44-year-old became interested in health and safety after a near-death experience at the age of five, when he almost choked on a marble. His mother was able to save him by holding him upside down and slapping him on the back until the marble dislodged. Mr Allen said the incident was a turning point in his life and led him to dedicate himself to safety education. More information and free training resources can be found at

Positive Interim 2-Year Data from enVVeno Medical's VenoValve Pivotal Study to be Presented Today at the Society for Vascular Surgery (SVS) 2025 Vascular Annual Meeting
Positive Interim 2-Year Data from enVVeno Medical's VenoValve Pivotal Study to be Presented Today at the Society for Vascular Surgery (SVS) 2025 Vascular Annual Meeting

Yahoo

time3 days ago

  • Yahoo

Positive Interim 2-Year Data from enVVeno Medical's VenoValve Pivotal Study to be Presented Today at the Society for Vascular Surgery (SVS) 2025 Vascular Annual Meeting

Interim two-year follow-up data from 42 subjects in the VenoValve pivotal trial show sustained clinical improvement and continued patient benefit at 24 months compared to baseline 83% of subjects maintained a clinically meaningful benefit with a 3 or more point improvement in Revised Venous Clinical Severity Score (rVCSS) 9.1 point average rVCSS improvement among the clinically meaningful benefit cohort Subjects experienced a median 74% improvement in leg pain Interim follow-up data indicate sustained improvements across all venous-specific quality-of-life (QoL) indicators A decision from the U.S. Food and Drug Administration (FDA) on the VenoValve is anticipated in the second half of 2025 Company to host live webcast with presenting Principal Investigator, today, June 6th at 11:20 AM ET / 10:20 AM CT - Access the Webcast Here IRVINE, CA / / June 6, 2025 / enVVeno Medical Corporation (Nasdaq:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of deep venous disease, today announced that interim two-year follow-up data on 42 subjects from the 75 person VenoValve U.S. pivotal trial will be presented today by lead enroller Dr. Cassius Iyad Ochoa Chaar, at the Society for Vascular Surgery (SVS) 2025 Vascular Annual Meeting (VAM25) being held June 4-7, 2025 in New Orleans, LA. Additionally, the Company announced it will host a live webcast to discuss these interim results today, Friday, June 6th at 11:20 AM ET / 10:20 AM CT (details below). Key interim two-year follow-up data being presented at VAM25 include: 83.3% of subjects (n=35/42) maintained a clinically meaningful benefit, defined as an improvement of 3 or more points in the revised Venous Clinical Severity Score (rVCSS). 9.1 point average rVCSS improvement among the responder cohort. A median 74% improvement in leg pain, as measured by the Visual Analog Scale (VAS). Wound healing outcomes in 17 subjects with 25 ulcers showed that 60% of ulcers healed completely, 24% decreased in size, and 16% increased in size. Patient-reported outcomes also demonstrated sustained improvements across all venous specific QoL indicators (VEINES-QoL/Sym). Among the subjects (n=30), a 100% valve patency rate. All values were calculated comparing each patient's baseline levels to the reported values at the patient's 24-month visit. The Revised Venous Clinical Severity Score (rVCSS) is a clinically validated scoring system used to track the progression or regression of venous diseases. "These interim two-year follow-up data demonstrate substantial and sustained improvement across all effectiveness endpoints at two years. This is extremely encouraging, especially when you consider that all the patients enrolled in the study had severe CVI and failed all other treatment options," said Robert Berman, enVVeno Medical's Chief Executive Officer. "Despite attempts over many decades, nobody has been able to create an effective treatment for severe CVI caused by malfunctioning valves in the deep veins of the leg. The VenoValve has the potential to change the treatment paradigm for deep venous CVI, both for the millions of patients suffering from severe CVI and the thousands of vascular surgeons who have been waiting for an effective treatment option." Dr. Cassius Iyad Ochoa Chaar, who is the Associate Professor of Surgery, Division of Vascular Surgery and Endovascular Therapy, Yale School of Medicine, will present the abstract titled, "Patients with Deep Venous Reflux Continue to Experience Clinical Improvement 2-year after Implantation of the VenoValve" today at VAM 2025. The VenoValve is a potential first-in-class, surgical replacement venous valve for patients with severe deep venous CVI. The Company estimates that there are approximately 2.5 million potential new patients each year in the U.S. that could be candidates for the VenoValve. The Company has submitted a pre-market authorization (PMA) application for the VenoValve to the U.S. Food and Drug Administration (FDA), with a decision anticipated in the second half of 2025. Webcast Details The Company will host a webcast presentation to discuss the results for investors, analysts and other interested parties today, June 6, 2025, at 11:20 AM ET / 10:20 AM CT. Joining enVVeno management for the event will be Dr. Chaar. The live webcast will be accessible on the Events page of the enVVeno website, and will be archived for 90 days. About CVI Severe, deep venous Chronic Venous Insufficiency (CVI) is a debilitating disease that is most often caused by blood clots (deep vein thromboses or DVTs) in the deep veins of the leg. When valves inside of the veins of the leg fail, blood flows in the wrong direction and pools in the lower leg, causing pressure within the veins of the leg to increase (venous hypertension). Symptoms of severe CVI include leg swelling, pain, edema, and in the most severe cases, recurrent open sores known as venous ulcers. The disease can severely impact everyday functions such as sleeping, bathing, dressing, and walking, and is known to result in high rates of depression and anxiety. There are currently no effective treatments for severe CVI of the deep vein system caused by valvular incompetence. Estimates indicate that CVI costs the U.S. healthcare system in excess of $4 billion each year. About enVVeno Medical Corporation enVVeno Medical (NASDAQ:NVNO) is an Irvine, California-based, late clinical-stage medical device Company focused on the advancement of innovative bioprosthetic (tissue-based) solutions to improve the standard of care for the treatment of deep venous disease. The Company's lead product, the VenoValve®, is a first-in-class surgical replacement venous valve being developed for the treatment of deep venous Chronic Venous Insufficiency (CVI). The Company is also developing a non-surgical, transcatheter based replacement venous valve for the treatment of deep venous CVI called enVVe®. Both the VenoValve and enVVe are designed to act as one-way valves, to help assist in propelling blood up the leg, and back to the heart and lungs. The VenoValve is currently being evaluated in the VenoValve U.S. pivotal study and the Company is currently performing the final testing necessary to seek approval for the pivotal trial for enVVe. Cautionary Note on Forward-Looking Statements This press release and any statements of stockholders, directors, employees, representatives and partners of enVVeno Medical Corporation (the "Company") related thereto contain, or may contain, among other things, certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve significant risks and uncertainties. Such statements may include, without limitation, statements identified by words such as "projects," "may," "will," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans," "potential" or similar expressions. These statements are based upon the current beliefs and expectations of the Company's management and are subject to significant risks and uncertainties, including those detailed in the Company's filings with the Securities and Exchange Commission. Actual results and timing (may differ significantly from those set forth or implied in the forward-looking statements. Forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors (many of which are beyond the Company's control). The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future presentations or otherwise, except as required by applicable law. INVESTOR CONTACT:Jenene Thomas, JTC Team, LLCNVNO@ 824-0775 MEDIA CONTACT:Glenn Silver, FINN 818-8198 SOURCE: enVVeno Medical Corporation View the original press release on ACCESS Newswire

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store